References
- 1. Chuang DT, Wynn RM, Shih VE. Maple syrup urine disease (branched-chain ketoaciduria). In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, editors. The online metabolic and molecular bases of inherited diseases. New York: McGraw-Hill; 2008. p. 1–42.
- 2. Muelly ER, Moore GJ, Bunce SC, Mack J, Bigler DC, Morton DH, et al. Biochemical correlates of neuropsychiatric illness in maple syrup urine disease. J Clin Invest 2013;123(4):1809-20.
- 3. Knerr I, Weinhold N, Vockley J, Gibson KM. Advances and challenges in the treatment of branched-chain amino/keto acid metabolic defects. J Inherit Metab Dis 2012;35(1):29-40.
- 4. Yudkoff M, Daikhin Y, Nissim I, Horyn O, Luhovyy B, Lazarow A, et al. Brain amino acid requirements and toxicity: the example of leucine. J Nutr 2005;135(6 Suppl):1531S-8S.
- 5. Strauss KA, Wardley B, Robinson D, Hendrickson C, Rider NL, Puffenberger EG, et al. Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab 2010;99(4):333–45.
- 6. Mescka CP, Guerreiro G, Hammerschmidt T, Faverzani J, de Moura Coelho D, Mandredini V, et al. L-Carnitine supplementation decreases DNA damage in treated MSUD patients. Mutat Res 2015;775:43-7.
- 7. Menkes JH, Hurst PL, Craig JM. A new syndrome: progressive familial infantile cerebral dysfunction associated with an unusual urinary substance. Pediatrics 1954;14(5):462–7.
- 8. Dancis J, Levits M, Westall RG. Maple syrup urine disease: branched-chain keto-aciduria. Pediatrics 1960;25:72-9.
- 9. Niu DM, Chien YH, Chiang CC, Ho HC, Hwu WL, Kao SM, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis 2010;33(Suppl 2):S295-305.
- 10. Axler O, Holmquist P. Intermittent maple syrup urine disease: two case reports. Pediatrics 2014;133(2):e458-60.
- 11. Singh RH, Rohr F, Splett PL. Bridging evidence and consensus methodology for inherited metabolic disorders: creating nutrition guidelines. J Eval Clin Pract 2013;19(4):584–90.
- 12. Mazariegos GV, Morton DH, Sindhi R, Soltys K, Nayyar N, Bond G, et al. Liver transplantation for classical maple syrup urine disease: long-term follow-up in 37 patients and comparative United Network for Organ Sharing experience. J Pediatr 2012;160(1):116–21.
- 13. Templier I, Reymond JL, Nguyen MA, Boujet C, Lantuejoul S, Beani JC, et al. Acrodermatitis enteropathica-like syndrome secondary to branched-chain amino acid deficiency during treatment of maple syrup urine disease. Ann Dermatol Venereol 2006;133(4):375-9.
- 14. Puzenat E, Durbise E, Fromentin C, Humbert P, Aubin F. Iatrogenic acrodermatitis enteropathica-like syndrome in leucinosis. Ann Dermatol Venereol 2004;131(8-9):801-4.
- 15. Tabanlioglu D, Ersoy-Evans S, Karaduman AE. Acrodermatitis enteropathica-like eruption in metabolic disorders: acrodermatitis dysmetabolica is proposed as a better term. Pediatr Dermatol 2009;26(2):150-4.
- 16. Arrora K, Das RR, Panda SS, Kabra M. Acrodermatitis enteropathica-like lesions in a neonate. BMJ Case Rep 2013;2013. doi:10.1136/bcr-2013-200190
- 17. Acrodermatitis enteropathica like eruption. In: El-Darouti MA. Challenging cases in dermatology. London: Springer Verlag; 2013. p. 95-9.
- 18. Domínguez-Cruz JJ, Bueno-Delgado M, Pereyra J, Bernabeu-Wittel J, Conejo-Mir J. Acrodermatitis enterophatica-like skin lesions secondary to isoleucine deficiency. Eur J Dermatol 2011;21(1):115-6.
- 19. Oztürk Y. Acrodermatitis enteropathica-like syndrome secondary to branched-chain amino acid deficiency in inborn errors of metabolism. Pediatr Dermatol 2008;25(3):415.
- 20. Frazier DM, Allgeier C, Homer C, Marriage BJ, Ogata B, Rohr F, et al. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. Mol Genet Metab 2014l;112(3):210-7.